These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 21909660)
1. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom? Forstpointner R; Dreyling M Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660 [TBL] [Abstract][Full Text] [Related]
2. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554 [TBL] [Abstract][Full Text] [Related]
3. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma. Hagenbeek A Transfus Apher Sci; 2013 Aug; 49(1):43. PubMed ID: 23932512 [No Abstract] [Full Text] [Related]
4. Rituximab maintenance versus retreatment in follicular lymphoma. Palla AR; Hamadani M Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794 [TBL] [Abstract][Full Text] [Related]
5. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527 [TBL] [Abstract][Full Text] [Related]
7. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. Pisani F; Maini CL; Sciuto R; Dessanti L; D'Andrea M; Assisi D; Petti MC J Exp Clin Cancer Res; 2011 Feb; 30(1):16. PubMed ID: 21303501 [TBL] [Abstract][Full Text] [Related]
8. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568 [TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy in follicular lymphoma. Illidge T; Morschhauser F Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624 [TBL] [Abstract][Full Text] [Related]
10. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857 [TBL] [Abstract][Full Text] [Related]
11. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127 [TBL] [Abstract][Full Text] [Related]
13. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients? Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448 [TBL] [Abstract][Full Text] [Related]
14. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079 [TBL] [Abstract][Full Text] [Related]
15. Treatment of follicular lymphoma: current status. Tilly H; Zelenetz A Leuk Lymphoma; 2008; 49 Suppl 1():7-17. PubMed ID: 18821428 [TBL] [Abstract][Full Text] [Related]
16. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report. Papajik T; Prochazka V; Raida L; Kubova Z; Myslivecek M; Drymlova J; Buriankova E; Kucerova L; Indrak K Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):109-12. PubMed ID: 17690751 [TBL] [Abstract][Full Text] [Related]
17. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444 [TBL] [Abstract][Full Text] [Related]
18. Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. Li ZM; Ghielmini M; Moccia AA Expert Rev Anticancer Ther; 2013 Mar; 13(3):313-25. PubMed ID: 23477518 [TBL] [Abstract][Full Text] [Related]
19. Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure? Chatal JF; Kraeber-Bodéré F; Barbet J Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1236-9. PubMed ID: 18330570 [No Abstract] [Full Text] [Related]
20. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line]. Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]